Lung cancer remains the world's leading cause of cancer-related death, and Poland has historically ranked among the countries with the highest morbidity and mortality from the disease. A key reason is late diagnosis: 30 to 57% of Polish patients already have distant metastases at the time of diagnosis, and national lung cancer resection rates of only 16 to 20% reflect how few patients are caught early enough for curative surgery.
Low-dose computed tomography (LDCT) screening programs were designed to address this by detecting small, early-stage tumors before patients develop symptoms. Two landmark trials - the National Lung Screening Trial (NLST) in the US showing a 20% reduction in lung cancer mortality and the NELSON study in the Netherlands and Belgium showing a 26 to 61% mortality reduction - established LDCT as an effective screening approach. Poland's first screening program began in Szczecin in April 2008.
While much screening research focuses on detection rates and cancer biology, less attention has been paid to how screening changes the day-to-day operations of the thoracic surgery departments that must then treat those detected cancers. This study fills that gap by examining the surgical aspects, procedural choices, hospitalization patterns, and complication profiles of patients detected through Poland's first LDCT screening program compared with those diagnosed outside it.
The study retrospectively analyzed 242 patients across three groups. Group 1a comprised 52 patients diagnosed through the LDCT screening program and operated on between April 2008 and December 2009. Group 1b comprised 87 patients surgically treated for lung cancer during the same period but diagnosed outside the screening program. Group 2 was a historical control of 103 patients treated in the 18 months before the screening program began (July 2006 to March 2008).
This three-group design allows two distinct comparisons: a concurrent comparison between screened and non-screened patients during the same time period (Groups 1a vs. 1b), which isolates the effect of screening from any secular trends in surgical practice; and a historical comparison between the screening period and the pre-screening era (Group 1a vs. Group 2), which captures the overall change in case profile that accompanies program implementation.
The Szczecin screening program enrolled professionally active patients aged 55 to 65 years with a history of at least 20 pack-years of smoking, regardless of gender. Over the full program duration (April 2008 to December 2010), 15,017 CT scans were performed, detecting lung cancer in 107 cases - a rate of 7.1 per 1,000 examinations. Among operated screening-detected patients, 68.8% had stage I disease at the time of detection.
Screening detection produced a dramatically earlier disease distribution: 50% of screened patients had stage IA cancer at the time of surgery, compared to 24.1% in the concurrent non-screened group (p=0.03) and 32.0% in the pre-screening historical control (p=0.025). T1a tumors (the smallest tumor category) occurred in 58.3% of screened patients versus 26.5% and 25.4% in the comparison groups - a highly significant difference (p=0.002 and p=0.001 respectively).
Tumor volume was significantly smaller in screened patients, with a median volume of 9.65 cubic centimeters versus 23.4 cm3 in the concurrent non-screened group (p=0.004) and 20.46 cm3 in the pre-screening group (p=0.01). This matters because tumor volume is an independent prognostic factor: five-year survival for adenocarcinoma less than 10 mm diameter is estimated at 97.9%, dropping to 68.1% for 10-20 mm tumors and 53.7% for 20-30 mm tumors.
The histological profile of screened cancers also differed significantly. Adenocarcinoma occurred in 57.7% of screened patients versus 34.5% in the concurrent non-screened group (p=0.012) and 37.9% in the pre-screening group (p=0.030). This enrichment for adenocarcinoma reflects CT's superior ability to visualize peripheral lung structures where adenocarcinoma preferentially develops, compared to centrally located squamous cell carcinomas that CT may miss or misattribute to vascular structures.
The type of surgery performed differed significantly between screened and non-screened patients. Lobectomy with mediastinal lymphadenectomy was performed significantly more often in the screened group than in Groups 1b and 2 combined (p=0.01). At the same time, pneumonectomy - the most extensive procedure removing an entire lung - occurred roughly 50% less frequently in screened patients than in the comparison groups. This shift reflects the earlier stage and smaller tumor size detected through screening.
Surgeries for screened patients were longer on average, with statistically significant differences versus both comparison groups (p=0.02 vs. Group 1b, p=0.007 vs. Group 2). The authors attribute this to the higher proportion of lobectomies with lymphadenectomy in the screened group - these are more technically demanding procedures than simpler resections. Notably, procedure duration did not correlate with complication rates (p=0.79).
Screened patients were less likely to require invasive diagnostic procedures before surgery. A tissue diagnosis was not achieved through invasive procedures (bronchoscopy, EBUS, mediastinoscopy, biopsy) approximately 1.6 times more often in screened patients than in other groups, though this difference did not reach statistical significance. Screening-detected small peripheral tumors are often not accessible by bronchoscopy and may proceed directly to surgical resection for both diagnostic and therapeutic purposes.
Hospitalization duration was significantly shorter during the screening period than in the pre-screening era, though no significant difference was found between screened and non-screened patients during the same period. This suggests that healthcare system-wide improvements in perioperative care (rather than screening itself) drove the reduction in hospital stays. The screened group had zero perioperative deaths, compared to 2.3% in the concurrent non-screened group and 2.9% in the pre-screening period.
Perioperative complication rates did not differ significantly between any of the three groups, despite the screened group undergoing more technically complex procedures. This finding addresses a key concern about screening programs: that detecting more cancers and performing more surgeries would increase aggregate surgical complications. The data show this was not the case - surgical quality was maintained even as case volumes and complexity changed.
A notable finding was the strong correlation between blood transfusion and perioperative complications in non-screened patients: among transfusion recipients, 39.3% experienced perioperative complications versus only 14.7% among those not requiring transfusions (p=0.0002 across all groups). This relationship was not significant in the screened group (p=0.6), possibly reflecting the less extensive surgeries (fewer pneumonectomies) and lower blood loss typical of earlier-stage operations.
The introduction of the LDCT screening program significantly increased the total number of lung cancer surgeries performed, creating measurable pressure on the thoracic surgery department's capacity. The number of primary lung cancer resections was significantly higher during the screening program period than before it (p less than 0.05). This volume increase has direct implications for surgical department planning: staffing, operating room scheduling, anesthesia capacity, and postoperative bed availability must all expand to accommodate screening-driven demand.
Waiting time for surgery was significantly shorter for screened patients than for the pre-screening historical group, likely reflecting operational adaptations made when the department integrated screening program management. Faster access to surgery for screen-detected early-stage disease maximizes the survival benefit of early detection - a cancer that doubles in volume every 100 to 200 days loses its stage IA advantage if surgery is delayed by months.
The shift in surgical case mix also has training and skill implications. More lobectomies with mediastinal lymphadenectomy and fewer pneumonectomies changes what skills surgical trainees develop. The screening era's emphasis on early-stage disease also coincided with the broader adoption of video-assisted thoracoscopic surgery (VATS), targeted molecular testing (EGFR mutations, PD-L1 expression), and liquid biopsy technologies - changes that collectively transformed the department's practice profile.
The study has important limitations that must be acknowledged. It was a pilot program conducted in a single city (Szczecin) with strict inclusion criteria (professionally active patients aged 55 to 65 with significant smoking history), limiting generalizability. The small screened cohort of 52 surgical cases restricts statistical power. Additionally, the study was conducted in 2008 to 2009 before the widespread availability of modern diagnostic tools, meaning both surgical techniques and diagnostic pathways have evolved substantially since.
Current technological advances in AI and radiomics are directly relevant to addressing the limitations of 2008-era LDCT screening. Deep learning-based convolutional neural networks have demonstrated higher nodule detection sensitivity than conventional reading, while automated volumetric analysis reduces false positive rates by objectively characterizing nodule growth dynamics. Blood-based biomarkers including circulating tumor DNA (cfDNA), methylation patterns, circulating tumor cells, and exhaled breath analysis complement CT findings to reduce unnecessary invasive follow-up procedures.
The study's core conclusion remains clinically relevant and actionable: LDCT screening fundamentally changes the surgical landscape by shifting detection to earlier, smaller, more resectable tumors and increasing the proportion of curative-intent procedures. The surgical improvements described - fewer pneumonectomies, shorter hospitalization, zero perioperative mortality in screened patients - validate the promise of screening from the perspective of the clinicians who must operationalize it, complementing the population-level mortality data from the NLST and NELSON trials.